Page 141 - 南京医科大学学报自然科学版
P. 141
第44卷第1期 夏经纬,沈 波. 肠道微生物在肺癌发生发展及治疗中的研究进展[J].
2024年1月 南京医科大学学报(自然科学版),2024,44(01):130-137 ·135 ·
微环境,降低放疗疗效,而共生细菌却有着截然相 [11] YAMAMURA K,IZUMI D,KANDIMALLA R,et al. In⁃
反的作用,并且肠道益生菌具有保护肠黏膜,减轻 tratumoral Fusobacterium nucleatum levels predict thera⁃
放疗不良反应的作用;肠道菌群与肺癌靶向治疗相 peutic response to neoadjuvant chemotherapy in esopha⁃
关的研究仍然处于起步阶段;在肺癌免疫治疗方 geal squamous cell carcinoma[J]. Clin Cancer Res,
2019,25(20):6170-6179
面,肠道菌群的作用已经得到了广泛认可。目前多
[12] GELLER L T,BARZILY⁃ROKNI M,DANINO T,et al.
项研究表明,肠道微生物的多样性、特定类群及以
Potential role of intratumor bacteria in mediating tumor
SCFA 为主的代谢产物可以通过活化免疫细胞、改
resistance to the chemotherapeutic drug gemcitabine[J].
善肿瘤微环境等方式来影响 ICI 的治疗效果。因
Science,2017,357(6356):1156-1160
此,未来的研究需要更加深入地探讨菌群与肺癌治 [13] ROUTY B,LE CHATELIER E,DEROSA L,et al. Gut mi⁃
疗的关系,并开发出更加有效的治疗策略。我们坚 crobiome influences efficacy of PD⁃1⁃based immunothera⁃
信,通过不断地研究和探索,肠道菌群将成为肺癌 py against epithelial tumors[J]. Science,2018,359
治疗中不可或缺的一部分,为肺癌患者带来更好的 (6371):91-97
治疗效果和预后。 [14] ZHENG Y,FANG Z,XUE Y,et al. Specific gut micro⁃
biome signature predicts the early⁃stage lung cancer[J].
[参考文献]
Gut Microbes,2020,11(4):1030-1042
[1] SIEGEL R L,MILLER K D,WAGLE N S,et al. Cancer [15] QIN X,BI L,YANG W,et al. Dysbiosis of the gut micro⁃
statistics,2023[J]. CA Cancer J Clin,2023,73(1):17- biome is associated with histopathology of lung cancer
48
[J]. Front Microbiol,2022,13:918823
[2] YOSHIDA K,GOWERS K H C,LEE⁃SIX H,et al. Tobacco [16] LIU F,LI J,GUAN Y,et al. Dysbiosis of the gut microbi⁃
smoking and somatic mutations in human bronchial ome is associated with tumor biomarkers in lung cancer
epithelium[J]. Nature,2020,578(7794):266-272 [J]. Int J Biol Sci,2019,15(11):2381-2392
[3] YANG J J,YU D X,SHU X O. Association of dietary fi⁃ [17] ALEXANDER J L,WILSON I D,TEARE J,et al. Gut mi⁃
ber and yogurt consumption with lung cancer risk:a crobiota modulation of chemotherapy efficacy and toxicity
pooled analysis[J]. JAMA Oncol,2020,6(2):e194107 [J]. Nat Rev Gastroenterol Hepatol,2017,14(6):356-
[4] HE Q Q,QU M Y,SHEN T Y,et al. Suppression of 365
VEGFD expression by S⁃nitrosylation promotes the deve⁃ [18] CURRÒ D. The role of gut microbiota in the modulation
lopment of lung adenocarcinoma[J]. J Exp Clin Cancer of drug action:a focus on some clinically significant issues
Res,2022,41(1):239 [J]. Expert Rev Clin Pharmacol,2018,11(2):171-183
[5] SHREINER A B,KAO J Y,YOUNG V B. The gut micro⁃ [19] KOPPEL N,MAINI REKDAL V,BALSKUS E P. Chemi⁃
biome in health and in disease[J]. Curr Opin Gastroenterol, cal transformation of xenobiotics by the human gut micro⁃
2015,31(1):69-75 biota[J]. Science,2017,356(6344):eaag2770
[6] DE MARTEL C,FERLAY J,FRANCESCHI S,et al. [20] ROUTY B,GOPALAKRISHNAN V,DAILLÈRE R,et al.
Global burden of cancers attributable to infections in The gut microbiota influences anticancer immunosurveil⁃
2008:a review and synthetic analysis[J]. Lancet Oncol, lance and general health[J]. Nat Rev Clin Oncol,2018,
2012,13(6):607-615 15(6):382-396
[7] FULBRIGHT L E,ELLERMANN M,ARTHUR J C. The [21] NAJMI M,TRAN T,WITT R G,et al. Modulation of the
microbiome and the hallmarks of cancer[J]. PLoS Pat⁃ gut microbiome to enhance immunotherapy response in
hog,2017,13(9):e1006480 metastatic melanoma patients:a clinical review[J]. Der⁃
[8] LEE M H,LOZANO G. Regulation of the p53 ⁃ MDM2 matol Ther,2022,12(11):2489-2497
pathway by 14⁃3⁃3 sigma and other proteins[J]. Semin [22] MATSON V,FESSLER J,BAO R Y,et al. The commen⁃
Cancer Biol,2006,16(3):225-234 sal microbiome is associated with anti⁃PD⁃ 1 efficacy in
[9] YANG H Y,WEN Y Y,CHEN C H,et al. 14⁃3⁃3 sigma metastatic melanoma patients[J]. Science,2018,359
positively regulates p53 and suppresses tumor growth[J]. (6371):104-108
Mol Cell Biol,2003,23(20):7096-7107 [23] CULLIN N,AZEVEDO ANTUNES C,STRAUSSMAN R,
[10] LAU H C H,YU J. Gut microbiome alters functions of mu⁃ et al. Microbiome and cancer[J]. Cancer Cell,2021,39
tant p53 to promote tumorigenesis[J]. Signal Transduct (10):1317-1341
Target Ther,2020,5(1):232 [24]DENK D,GRETEN F R. Inflammation:the incubator of